Report top-line data for EB-101 Phase 3 VIITAL™ study

Delivered after the deadline (34 days after the deadline)

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 15 Nov 2021
Due: 30 Sep 2022
Delivered: 3 Nov 2022

Deadline
Met
Late
Not met
Today

What the company said

“top-line data readout in the third quarter of 2022”

SourceAbeona Therapeutics Inc. Form 8-K press release, 2021-11-15
FilingSEC filing index
Deadline as statedthird quarter of 2022
Deadline used30 Sep 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-ABEO-003379
Cite as https://keptindex.org/c/KI-C-2021-ABEO-003379/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced the top-line data for the VIITAL™ study on November 3, 2022, which occurred after the third quarter 2022 deadline.

A
Abeona Therapeutics Inc. 10-K filed 2023-03-29 Regulatory filing · published 29 Mar 2023 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint 8f0dd2cf4108
“On November 3, 2022, we announced positive topline data from VIITAL™ study.” ✓ confirmed on the page

Market reaction: the shares moved -2.1% against the S&P 500 over the three sessions around the disclosure (28 Mar 2023 to 31 Mar 2023). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 15 Nov 2021

Deadline 30 Sep 2022 (“third quarter of 2022”)
Version 2 · stated 13 May 2022

Deadline 30 Sep 2022 (“in 3Q 2022”) · wording expected

“Focus R&D resources on EB-101 pivotal phase 3 VIITAL™ topline data expected in 3Q 2022”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: EB-101 top-line data
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Abeona Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.